Original Publication Date: 5 June, 2014
Publication / Source: International Journal of Hematologic Oncology
Authors: Omotayo Fasan, Belinda R Avalos & Edward A Copelan
Treatment of acute myeloid leukemia (AML) in nonelderly patients has followed the same paradigm of remission induction with cytarabine and anthracycline with or without a third cytotoxic drug for more than 40 years. These drugs produce complete remissions in the majority of patients, but cure requires intensive postremission treatment. Postremission therapies have also remained similar for many years, but better criteria for selection of postremission treatment for individual patients has improved results.